Redx celebrates breakthrough antibiotics development

Redx celebrates breakthrough antibiotics development

Redx Pharma has developed a series of compounds which have successfully completed two vivo infection studies which show the programme has the potential to create the first new class of broad spectrum antibiotics in 30 years.

The research, conducted by Redx at its facilities at Alderley Park, Cheshire, found the compounds are highly effective against a range of drug resistant bacteria including Gram negative species such as E. coli and Pseudomonas which can be responsible for drug resistant forms of pneumonia, urinary tract infections, intra-abdominal infections and septicaemia.

Neil Murray, chief executive of Redx Pharma, said: “We have put an enormous research focus on fighting drug-resistant infection over the last three years and are excited by the breakthrough that our team has made. Currently more than 50,000 people in Europe and the US alone die annually because of antibiotic resistance and the problem is getting worse year-on-year. It is predicted that globally all drug-resistant infection will claim the lives of 10 million people annually by 2050 if we do not find a solution to this critical problem. Developing a truly broad spectrum antibiotic that can treat infections caused by both Gram-negative, as well as Gram-positive bacteria, would therefore be a major breakthrough in the battle to combat life threatening diseases worldwide.”


See the article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.